At the Biotech Conclave 2026, Bharat Biotech co-founder Suchitra Ella advised biotechnology students to look beyond academic boundaries, gain industry exposure, and master business and computational skills to thrive in the evolving life sciences sector.
- Students must actively seek exposure outside academic campuses in industrial and research laboratories.
- To succeed as a biotech entrepreneur, understanding business, marketing, supply chains, and policy is critical.
- Artificial Intelligence (AI) accelerates research timelines but can never replace hands-on wet-lab scientific work.
Delivering a powerful address at the Biotech Conclave 2026, presented by VIT Chennai in association with The Hindu, Suchitra Ella, co-founder and managing director of Bharat Biotech and CII President-Designate, urged biotechnology students to break free from academic silos. Speaking at the Taj Connemara in Chennai, she emphasized that the rapidly evolving life sciences sector demands professionals who can transcend traditional educational boundaries.
Dr. Ella advised students to seek opportunities in research laboratories and institutions outside their immediate academic environments. She noted that relying solely on a chosen curriculum or specialization is no longer sufficient in an industry characterized by rapid technological integration and global challenges.
Understanding the Business of Science
Addressing a question on whether being a brilliant scientist is enough to succeed, Dr. Ella highlighted that biotechnology entrepreneurship requires a multi-dimensional approach. She stated that modern biotech leaders must understand commercial operations, marketing, distribution, supply chains, and government relations. According to her, as an organization grows, an entrepreneur cannot remain constrained by academic qualifications and must learn to wear "multiple hats."
Furthermore, Dr. Ella urged students to balance wet-lab expertise with computational skills. Discussing the perceived divide between wet-lab bioprocessing and AI-driven discovery, she maintained that both domains are equally vital. However, she clarified that hands-on, empirical science remains the indispensable starting point of all biological innovations.
Why This Matters
BozokMedia analysis shows that the global biotechnology sector is shifting toward interdisciplinary leadership. The modern life sciences landscape no longer rewards isolated academic excellence; instead, it values individuals who can bridge the gap between complex laboratory research and commercial viability, ensuring that life-saving innovations reach the market efficiently.
"We need to let go when we see the data; projects must be stopped if safety results are not convincing, rather than relying on theoretical expectations." - Suchitra Ella
On the critical question of when a researcher should abandon a project, Dr. Ella advised that decisions must be strictly guided by experimental, safety, and regulatory data rather than theoretical optimism. Additionally, addressing the integration of AI, she remarked that while AI can significantly reduce clinical trial timelines and enhance data analysis, it cannot function as a 100% operational driver or replace human scientists in wet-lab environments.
| Feature | AI-Driven Discovery | Wet-Lab Bioprocessing |
|---|---|---|
| Primary Function | Data analysis, predictions, and timeline reduction | Empirical experimentation and physical validation |
| Process Speed | Rapid and highly scalable | Time-intensive and highly regulated |
| Operational Role | Supportive and analytical tool | Core operational driver and foundation |
Frequently Asked Questions
1. What is the primary advice Dr. Suchitra Ella gave to biotech students?
She advised students to step out of their academic comfort zones, gain hands-on experience in external research labs, and acquire interdisciplinary skills including business management and policy understanding.
2. Can Artificial Intelligence replace wet-lab scientists in biotechnology?
No. While AI is an excellent tool for data processing and accelerating timelines, Dr. Ella emphasized that it cannot replace human scientists or act as a standalone operational driver in life sciences.
